Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial
- PMID: 11748755
- DOI: 10.1002/mds.1204
Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial
Abstract
This open study assessed the ability of rivastigmine to treat the neuropsychiatric complications of advanced Parkinson's disease. In a group of 12 patients, hallucinations, sleep disturbance, and carer distress were all improved and cognitive performance significantly enhanced by the drug.
Copyright 2001 Movement Disorder Society.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical